(Patient must have an R.G.C.C. IMMUNE FRAME and ONCOTRACE within the last 6 months.)
21-25 Days (from the day the sample reaches lab)
Follow up blood samples should be sent to our lab at specific time points (Day 120 and Day 210). They will be used to assess VAXO-Q-RE efficiency for each individual and generate a report.
Vaxo-Q-Re is a new advanced therapy consisting of five types of immune cells; macrophages, NK cells, dendritic cells, cytotoxic T lymphocytes and antibody producing plasma cells. Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Vaxo-Q-Re has been in development by RGCC scientists for more than five years and is now categorized as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA).